Abbreviations
death, Tumorstreatment‐related
ONCOLOGY
adverse eventblinded independent central reviewconfidence intervalcombined positive scoreduration of responseesophageal adenocarcinomaEastern Cooperative Oncology Group performance statusoxaliplatin, leucovorin and 5‐fluorouracilgastric cancergastroesophageal junction cancerhuman epidermal growth factor receptor 2hazard ratiolower limit of normalmicrosatellite instability‐highmicrosatellite stableobjective response rateoverall survivalprogrammed death‐1programmed death ligand 1progression‐free survivalevery 2 weeksevery 3 weeksResponse Evaluation Criteria in Solid Tumorstreatment‐related adverse eventcapecitabine and oxaliplatin